|
Based on the new IMS
World Review,
global audited pharma sales grew 12% in 2001 to reach $364.2
billion. North America was again the most dynamic region,
with 17% growth to $181.8 billion - half of all global sales.
The IMS World Review
tracks actual sales of approximately 90% of all prescription
drugs and certain over-the-counter products in more than
70 countries. Proprietary data projection methodologies
are then used to estimate total global pharmaceutical sales,
which grew to $392 billion in 2001. Audited sales rose 12%
at a constant US dollar rate, to $364.2 billion, compared
to $321.8 billion in 2000
"The global pharmaceutical
industry experienced sustained robust growth in 2001, despite
the economic challenges facing some of the world’s leading
markets," said Graham Lewis, IMS Vice President, Strategic
Consulting. "North America remains the most dynamic
region, and while we expect more moderate sales growth in
the US this year, it will continue to grow more quickly
than other key markets."
North America, Europe and Japan
accounted for 87% of audited worldwide pharmaceutical consumption
in 2001. Setting the pace among the leading regions, North
American pharmaceutical sales grew 17% to $181.8 billion,
representing half of all global sales in 2001. Europe
experienced solid sales growth of 10%, to $88.0 billion,
and Japan saw moderate growth of 4%, to $47.6 billion. With
$18.9 billion in 2001 pharmaceutical sales, growth in Latin
America was flat, while sales in Asia (excluding Japan),
Africa and Australia were $27.9 billion, up 9%.
2001 Global
pharma sales by region
|
World
Audited Market
|
2001
Sales ($bn)
|
% Global
sales ($)
|
% Growth
(constant $)
|
| North
America |
$181.8
|
50%
|
+17%
|
| Europe |
88.0
|
24
|
+10
|
| Japan
|
47.6
|
13
|
+4
|
| Asia,
Africa and Australia |
27.9
|
8
|
+9
|
| Latin
America |
18.9
|
5
|
+0.1
|
| TOTAL
|
$364.2bn
|
100.0%
|
+12%
|
Source: IMS World Review 2002 and IMS Consulting.
Sales cover direct and indirect pharmaceutical channel purchases
in US dollars from pharmaceutical wholesalers and manufacturers.
The figures above represent 52 weeks of sales data, and
include prescription and certain OTC data, exclude US home
healthcare sales, and represent manufacturer prices.
"The sustained growth of
the world pharmaceutical market shows that consumers and
healthcare professionals continue to appreciate the value
of pharmaceuticals as a convenient, cost-effective form
of treatment," said Dr Joe Zammit-Lucia, president
of Cambridge Pharma Consultancy, an IMS company.
"One noticeable trend in 2001 was fewer
significant new products
reaching the market compared to recent years. Going into
2002, pharma CEOs have three items at the top of their agendas:
- improving the productivity
of their considerable R&D investments
- getting a better return
on their growing marketing and sales expenditures
- and effectively managing
global pricing policies that continue to threaten intellectual
property rights.
The outlook for the industry
as a whole remains positive – but performance will vary
significantly among companies."
Leading therapy classes
The top ten therapy classes accounted
for 32% of the total audited world market in 2001. Four
of the leading ten - cholesterol & triglyceride reducers,
antipsychotics,
oral antidiabetics and systemic antihistamines - grew more
than 20%, with antipsychotics and oral antidiabetics sales
each up 30%. Antihistamines replaced non-narcotic analgesics
in the top ten.
Antiulcerants
totalled $19.5 billion in sales in 2001, and remained the
leading therapeutic class worldwide, as it has for the past
11 years. Representing 6% of all audited global pharmaceutical
sales, antiulcerant sales were up 14% from 2000. AstraZeneca’s
Losec/Prilosec,
the world’s leading ulcer product and second best-selling
drug overall, accounted for $6.1 billion, or 32%, of all
sales in this class.
The second-ranked therapy class,
cholesterol
& triglyceride reducers,
grew 22% to $18.9 billion in 2001. Contributing to the growth
was strong demand for Pfizer’s Lipitor, the top-selling
drug worldwide. Lipitor sales rose 31% to $7.0 billion.
Antidepressants, the third-ranked therapy class, experienced
20% growth in 2001, to $15.9 billion.
Leading therapy classes in 2001 global pharmaceutical
sales*
|
Rank
|
Audited
World Therapy Class
|
2001
Sales ($bn)
|
% Global
sales ($)
|
% Growth
(constant $)
|
|
1
|
Antiulcerants
|
19.5
|
6%
|
+14%
|
|
2
|
Cholest. & Triglyceride
Reducers
|
18.9
|
5
|
+22
|
|
3
|
Antidepressants
|
15.9
|
5
|
+20
|
|
4
|
Antirheumatic Non-Steroidals
|
10.9
|
3
|
+16
|
|
5
|
Calcium Antagonists,
Plain
|
9.9
|
3
|
+4
|
|
6
|
Antipsychotics
|
7.7
|
2
|
+30
|
|
7
|
Oral Antidiabetics
|
7.6
|
2
|
+30
|
|
8
|
ACE Inhibitors, Plain
|
7.5
|
2
|
+5
|
|
9
|
Cephalosporins &
Combinations
|
6.7
|
2
|
0
|
|
10
|
Antihistamines, Systemic
|
6.7
|
2
|
+22
|
|
|
Total
Leading 10 ATCs at Level 3
|
$111.3bn
|
32
|
+16%
|
Source: IMS World Review 2002. *Note: The figures
above reflect 53 weeks of US sales data instead of 52 weeks,
an adjustment that is made every five years to bring IMS’
data tracking methodology into line with the calendar year.
As a result, US figures in this table incorporate five additional
days of sales.
Leading products
The top ten best-selling drugs
worldwide accounted for $40.2 billion in sales in 2001,
a 22% increase over 2000. Within the total audited world
market, Lipitor was the top-selling drug in 2001, with $7.0
billion in sales, compared with $5.4 billion in 2000. It
overtook Losec/Prilosec, the top-ranked drug in 2000,
which achieved 2001 sales of $6.1 billion on flat growth.
Merck & Co’s cholesterol-lowering drug Zocor
is ranked third, with $5.3 billion in sales and 25% growth.
Of the ten best-selling drugs
in 2001, the fastest-growing worldwide was Merck’s arthritis
drug Vioxx, with sales rising 44% year-over-year
to $2.6 billion. Pharmacia and Pfizer’s competing COX-2
inhibitor, Celebrex,
generated $3.1 billion in sales, a 32% increase. Vioxx replaced
Pfizer’s antidepressant Zoloft as the tenth best-selling
product, and due to its US
patent expiry, Eli
Lilly’s antidepressant Prozac dropped out of the
top ten completely, having been the sixth best-selling drug
in 2000; Johnson & Johnson’s anemia drug Erypo
entered the product list in its stead.
Leading products
in 2001 global pharmaceutical sales*
|
Rank
|
Audited World Product
Sales
|
2001
sales ($bn)
|
% Growth
(Constant $)
|
|
1
|
Lipitor
|
7.0
|
+31%
|
|
2
|
Losec/Prilosec
|
6.1
|
0
|
|
3
|
Zocor
|
5.3
|
+25
|
|
4
|
Norvasc
|
3.7
|
+14
|
|
5
|
Ogastro/Prevacid
|
3.5
|
+13
|
|
6
|
Zyprexa
|
3.2
|
+35
|
|
7
|
Celebrex
|
3.1
|
+32
|
|
8
|
Erypo
|
2.9
|
+35
|
|
9
|
Seroxat/Paxil
|
2.8
|
+19
|
|
10
|
Vioxx
|
2.6
|
+44
|
|
|
Total 10 Leading Products
|
$40.2bn
|
+22%
|
Source: IMS World Review 2002.
*Note: 53 weeks US sales data as above.
IMS World Review
is compiled using IMS’ MIDAS™;
global analysis system, which captures pharmaceutical activity
from more than 70 countries. Growth in sales is measured
in constant dollars, enabling analyses without the influence
of fluctuating currency exchange rates. Pharmaceutical sales
figures include prescription and certain OTC data, and represent
manufacturer prices. For a full explanation of figures and
collection methods see Data
Value and definitions.
For further details about IMS
World Review 2002, please contact Paul
Jenner.
|
